Results 201 to 210 of about 346,103 (330)

Chronic myeloid leukemia

HemaSphere, 2019
openaire   +4 more sources

Efficacy, Safety, Pharmacokinetics, and Immunogenicity of ABBV‐154 in Adults With Glucocorticoid‐Dependent Polymyalgia Rheumatica: A Phase 2, Randomized, Double‐Blind, Placebo‐Controlled Trial

Arthritis &Rheumatology, EarlyView.
Objective An unmet need exists for glucocorticoid‐sparing treatments for patients with polymyalgia rheumatica (PMR). The antibody‐drug conjugate ABBV‐154 comprises adalimumab conjugated to a glucocorticoid receptor modulator. We evaluated ABBV‐154 versus placebo in patients with glucocorticoid‐dependent PMR.
Robert F. Spiera, Valerie Devauchelle‐Pensec, Claire E. Owen, Federico Díaz‐González, Tsutomu Takeuchi, Edit Drescher, Jaclyn Anderson, Dilek Arikan, Ronilda D'Cunha, Julie Parmentier, Denise T. Kruzikas, Weihan Zhao, Yang Yang, Karen Stellpflug, Frank Buttgereit   +14 more
wiley   +1 more source

Malignant progression of liver cancer progenitors requires lysine acetyltransferase 7–acetylated and cytoplasm‐translocated G protein GαS

Hepatology, EarlyView., 2022
KAT7‐acetylated and cytoplasm‐translocated G‐protein GαS enhances IL‐6 effect and drives HCC progenitor cell progression. Abstract Background and Aims Hepatocarcinogenesis goes through HCC progenitor cells (HcPCs) to fully established HCC, and the mechanisms driving the development of HcPCs are still largely unknown.
Ye Zhou, Kaiwei Jia, Suyuan Wang, Zhenyang Li, Yunhui Li, Shan Lu, Yingyun Yang, Liyuan Zhang, Mu Wang, Yue Dong, Luxin Zhang, Wannian Zhang, Nan Li, Yizhi Yu, Xuetao Cao, Jin Hou   +15 more
wiley   +1 more source

Expert Perspectives on a Clinical Challenge: Hematologic Malignancies and Vasculitis

Arthritis &Rheumatology, Accepted Article.
Systemic vasculitis describes a collection of rare diseases each caused by inflammation of blood vessel walls that can cause severe systemic complications [[3, 4]](#ref‐0003). The pattern of vascular inflammation and resultant damage is frequently variable and may be mimicked, or directly triggered, by infection or malignancy.
Michelle L. Robinette, Hetty E. Carraway
wiley   +1 more source

Mechanisms underlying synergism between circularized tumor necrosis factor‐related apoptosis inducing ligand and bortezomib in bortezomib‐sensitive or ‐resistant myeloma cells

Hematological Oncology, Volume 40, Issue 5, Page 999-1008, December 2022., 2022
Abstract Mechanisms underlying interactions between a novel, clinically relevant circularized tumor necrosis factor‐related apoptosis inducing ligand (TRAIL) agonist, circularly permuted TRAIL (CPT) have been examined in multiple myeloma (MM) cells sensitive or resistant to bortezomib (BTZ).
Yun Leng, Xiaoyan Hu, Lin Li, Jewel Nkwocha, Toshihisa Satta, Kanika Sharma, Maciej Kmeiciak, Huixing Zhou, Zhiyao Zhang, Liang Zhou, Wenming Chen, Steven Grant   +11 more
wiley   +1 more source

Secondary infections worsen the outcome of COVID‐19 in patients with hematological malignancies: A report from the ITA‐HEMA‐COV

Hematological Oncology, Volume 40, Issue 5, Page 846-856, December 2022., 2022
Abstract The impact of secondary infections (SI) on COVID‐19 outcome in patients with hematological malignancies (HM) is scarcely documented. To evaluate incidence, clinical characteristics, and outcome of SI, we analyzed the microbiologically documented SI in a large multicenter cohort of adult HM patients with COVID‐19.
Patrizia Zappasodi, Chiara Cattaneo, Virginia Valeria Ferretti, Roberto Mina, Andrés José María Ferreri, Francesco Merli, Margherita Oberti, Mauro Krampera, Alessandra Romano, Caterina Zerbi, Jacqueline Ferrari, Michele Cavo, Marco Salvini, Lorenza Bertù, Nicola Stefano Fracchiolla, Francesco Marchesi, Massimo Massaia, Vincenzo Marasco, Roberto Cairoli, Anna Maria Scattolin, Alessandro Maria Vannucchi, Carlo Gambacorti‐Passerini, Pellegrino Musto, Filippo Gherlinzoni, Antonio Cuneo, Antonello Pinto, Livio Trentin, Monica Bocchia, Sara Galimberti, Elisa Coviello, Maria Chiara Tisi, Alessandro Morotti, Brunangelo Falini, Mauro Turrini, Agostino Tafuri, Atto Billio, Massimo Gentile, Roberto Massimo Lemoli, Adriano Venditti, Matteo Giovanni Della Porta, Francesco Lanza, Luigi Rigacci, Patrizia Tosi, Sara Mohamed, Alessandro Corso, Mario Luppi, Nicola Giuliani, Alessandro Busca, Livio Pagano, Raffaele Bruno, Paolo Antonio Grossi, Paolo Corradini, Francesco Passamonti, Luca Arcaini, on behalf of the ITA‐HEMA‐COV Investigators   +54 more
wiley   +1 more source

AKI in chronic myeloid leukemia: remember lysozyme-induced nephropathy. [PDF]

J Bras Nefrol
Santos A, Marques N, Pestana R.
europepmc   +1 more source

Acute myeloid leukemia

HemaSphere, 2019
openaire   +3 more sources

Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia [PDF]

, 2017
et al.,, Uy, Geoffrey L
core   +2 more sources

Is Enhancer Function Driven by Protein–Protein Interactions? From Bacteria to Leukemia

BioEssays, EarlyView.
Enhancers are key regulatory elements that are conceptually conserved from bacteria to humans. Enhancer dysregulation is common in cancers, including leukemia. We argue that highly specific protein–protein interactions, including transcription factors, mediate enhancer‐promoter proximity to allow enhancer‐bound factors to directly act on RNA polymerase
Nicholas T. Crump, Thomas A. Milne
wiley   +1 more source